Latest Pharmaceuticals And Biotechnology News

Page 2 of 2
Cann Group Limited has disclosed a late payment of over $1.37 million in interest and facility fees to National Australia Bank, which has issued a non-waiver letter but is holding off on immediate action. The company is actively negotiating financing arrangements and plans to update the market by the end of September 2025.
Ada Torres
Ada Torres
8 Sept 2025
Algorae Pharmaceuticals reported a 62% reduction in net loss for FY2025, driven by R&D tax credits and cost efficiencies, while making significant strides in its AI drug discovery platform and therapeutic candidates.
Ada Torres
Ada Torres
28 Aug 2025
Telix Pharmaceuticals reported a robust 63% increase in revenue to $390.4 million for the first half of 2025, driven by strong Illuccix sales and the acquisition of RLS Radiopharmacies. Despite this growth, the company recorded a net loss of $2.3 million, reflecting increased investments and finance costs.
Ada Torres
Ada Torres
21 Aug 2025
Cann Group Limited has received a $315,552 advance on its expected FY2025 Research and Development Tax Incentive, marking the second tranche of funding to support its ongoing cannabis medicine development.
Ada Torres
Ada Torres
16 June 2025
Cyclopharm Limited has secured the maximum five-year U.S. patent extension for its flagship Technegas® Kit, extending market exclusivity to 2031 and reinforcing its strategic foothold in pulmonary imaging.
Ada Torres
Ada Torres
11 June 2025

Browse the archive

Full archive